Nothing Special   »   [go: up one dir, main page]

Mohan et al., 2015 - Google Patents

Preparation, in vitro and in vivo characterization of solid dispersions of lamotrigine using solvent evaporation technique

Mohan et al., 2015

View PDF
Document ID
10557954183790625483
Author
Mohan A
Madhavi M
Swetha G
Jyosthna P
Publication year
Publication venue
IOSR J Pharm

External Links

Snippet

Lamotrigine is one of the newer antiepileptic drugs and low aqueous solubility of Lamotrigine is responsible for its poor dissolution and delayed onset of action. The purpose of the present investigation is to increase the dissolution rate of Lamotrigine by preparing its …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/08—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Similar Documents

Publication Publication Date Title
Manna et al. Impregnation of PVP microparticles with ketoprofen in the presence of supercritical CO2
Chen et al. Comparative pharmacokinetics and bioavailability studies of quercetin, kaempferol and isorhamnetin after oral administration of Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes and Ginkgo biloba extract solid dispersions in rats
Golsefidi et al. Design, synthesis and evaluation of a molecularly imprinted polymer for hollow fiber–solid phase microextraction of chlorogenic acid in medicinal plants
Choi et al. Design of PVP/VA S-630 based tadalafil solid dispersion to enhance the dissolution rate
US7150766B2 (en) Method of particle formation
JP7289537B2 (en) Poloxamer compositions free of long-circulating substances, methods for their production and uses thereof
CN101543476B (en) A kind of naringin solid dispersion and its preparation method and application
Fu et al. Matrine-imprinted monolithic stationary phase for extraction and purification of matrine from Sophorae flavescentis Ait
Letchmanan et al. Enhanced dissolution and stability of artemisinin by nano-confinement in ordered mesoporous SBA-15 particles
Motlekar et al. Preparation and characterization of genistein containing poly (ethylene glycol) microparticles
Mohan et al. Preparation, in vitro and in vivo characterization of solid dispersions of oxcarbazepine using melting technique
CN102755627B (en) Method for preparing goserelin slow-release implant
Liang et al. In situ hexagonal liquid crystal for intra-articular delivery of sinomenine hydrochloride
Mohan et al. Preparation, in vitro and in vivo characterization of solid dispersions of lamotrigine using solvent evaporation technique
Sun et al. Response surface methodology to optimize the preparation of tosufloxacin tosylate/hydroxypropyl-β-cyclodextrin inclusion complex by supercritical antisolvent process
Shetty et al. Investigating the influence of the type of polymer on sustaining the supersaturation from amorphous solid dispersions of Apremilast and its pharmacokinetics
Zhang et al. Amino acid-PEGylated resveratrol and its influence on solubility and the controlled release behavior
EP1267836B1 (en) Process for the preparation of accelerated release formulations using compressed fluids
KR100728997B1 (en) Method for preparing solid dispersion of poorly soluble drug using supercritical fluid process
Rubim et al. Amiodarone hydrochloride: enhancement of solubility and dissolution rate by solid dispersion technique
Cardea et al. Supercritical CO2 assisted formation of poly (vinylidenefluoride) aerogels containing amoxicillin, used as controlled release device
Yan et al. An attempt to stabilize tanshinone IIA solid dispersion by the use of ternary systems with nano-CaCO3 and poloxamer 188
Hareeja et al. Formulation and in-vitro evaluation of spherical crystal agglomerates of ebastine by quasi emulsion solvent diffusion method
Wu et al. Bioavailability of 10-hydroxycamptothecin-phospholipid complex loaded by solid dispersion and lipid-based formulations
Fattah et al. Modulation of Clonazepam Solubility using Solid Dispersion Technique Improves its Solubility and Bioavailability.